Ryosuke Okamura

Also affiliated with Kyoto University Hospital

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 3%percentile

1.0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine

JCO Precision Oncology(2022)10.1200/po.20.00508

Top 22%

0.918DataRank

Top 22%17 citations

Ramez N. Eskander, Jason K. Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +8 more

Papers

Driven by 20 papers — median percentile 53. Top paper: “SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer”.

SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer

JCI Insight(2021)10.1172/jci.insight.150453

N/A

2.2DataRank · unranked

68 citations

Shumei Kato, Hitendra Patel, Paul T. Fanta, Suzanna Lee, Ryosuke Okamura +2 more

Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

Genome Medicine(2021)10.1186/s13073-021-00969-w

N/A

1.9DataRank · unranked

90 citations

Shumei Kato, Ryosuke Okamura, Hitendra Patel, Mina Nikanjam, Paul T. Fanta +14 more

Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens

JCI Insight(2021)10.1172/jci.insight.142547

N/A

1.1DataRank · unranked

31 citations

Ryosuke Okamura, Jacob J. Adashek, Noor Khalid, Suzanna Lee, Van Thomas Nguyen +3 more

Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine

JCO Precision Oncology(2022)10.1200/po.20.00508

Top 22%

0.918DataRank

Top 22%17 citations

Ramez N. Eskander, Jason K. Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +8 more

High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-20-0161

N/A

0.700DataRank · unranked

105 citations

Aaron M. Goodman, Ryosuke Okamura, Donald A. Barkauskas, Theresa J. Whitchurch, Suzanna Lee +9 more

Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies

npj Precision Oncology(2022)10.1038/s41698-022-00259-7

Top 71%

0.123DataRank

Top 71%1 citations

Razelle Kurzrock, Suzanna Lee, Ryosuke Okamura, Hyo Jeong Lim, Ki Hwan Kim +3 more

Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience

The Oncologist(2020)10.1002/onco.13532

N/A

0DataRank · unranked

8 citations

Jason K. Sicklick, Shumei Kato, Ryosuke Okamura, Vincent A. Miller, Brian Leyland‐Jones +3 more

Targeting G1-S phase cell-cycle alterations with CDK4/6 inhibitor-based genomically matched personalized therapy approach.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3623

N/A

0DataRank · unranked

1 citations

Shumei Kato, Ryosuke Okamura, Noor Khalid, Suzanna Lee, Van Thomas Nguyen +3 more

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3761

N/A

0DataRank · unranked

41 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more

High prevalence of clonal hematopoiesis‐type genomic abnormalities in cell‐freeDNAin invasive gliomas after treatment

International Journal of Cancer(2021)10.1002/ijc.33481

N/A

0DataRank · unranked

31 citations

David Piccioni, Amélie Boichard, Suzanna Lee, Rebecca E. Jimenez, Jason K. Sicklick +3 more

Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy

npj Precision Oncology(2022)10.1038/s41698-022-00309-0

N/A

0DataRank · unranked

17 citations

Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Ramez N. Eskander +7 more

Multi‐omic analysis in carcinoma of unknown primary ( CUP ): therapeutic impact of knowing the unknown

Molecular Oncology(2022)10.1002/1878-0261.13293

N/A

0DataRank · unranked

12 citations

Sophia Gumas, Jacob J. Adashek, Ryosuke Okamura, Suzanna Lee, Jason K. Sicklick +2 more

Data from Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

(2023)10.1158/1078-0432.c.6529977

N/A

0DataRank · unranked

0 citations

Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee +3 more

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2019-000438

N/A

0DataRank · unranked

191 citations

Shumei Kato, Suzanna Lee, Rebecca E. Jimenez, Jason K. Sicklick, Razelle Kurzrock +1 more

Molecular Tumor Board for Unicorns: Outcomes for rare and ultra-rare cancers using an N-of-One personalized treatment strategy

iScience(2024)10.1016/j.isci.2024.110465

N/A

0DataRank · unranked

10 citations

Shumei Kato, Jordan S. Lim, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura +6 more

Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy

Nature Communications(2020)10.1038/s41467-020-18613-3

N/A

0DataRank · unranked

303 citations

Ki Hwan Kim, Hyo Jeong Lim, Amélie Boichard, Mina Nikanjam, Elizabeth Weihe +17 more

MHC-I genotype and tumor mutational burden predict response to immunotherapy

Genome Medicine(2020)10.1186/s13073-020-00743-4

N/A

0DataRank · unranked

115 citations

Andrea Castro, Rachel Marty Pyke, Ryosuke Okamura, Shumei Kato, Paul Riviere +7 more

Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers

International Journal of Cancer(2020)10.1002/ijc.33230

N/A

0DataRank · unranked

75 citations

Razelle Kurzrock, Robert J. Mallory, Paul T. Fanta, Adam M. Burgoyne, Bryan M. Clary +3 more

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

OncoImmunology(2020)10.1080/2162402x.2019.1708065

N/A

0DataRank · unranked

68 citations

Ryosuke Okamura, Yuichi Kumaki, Sadakatsu Ikeda, Mina Nikanjam, Ramez N. Eskander +9 more

Precision oncology: the intention-to-treat analysis fallacy

European Journal of Cancer(2020)10.1016/j.ejca.2020.04.002

N/A

0DataRank · unranked

8 citations

Shumei Kato, Ryosuke Okamura, Razelle Kurzrock, Jason K. Sicklick

Ryosuke Okamura

Indexed papers

Top data-sharing exemplar

Papers